Location: Menlo Park, CA
CIK: 0002010850 · Show all filings
Period: Q2 2026 (← Previous)
Filing Date: Aug 14, 2026
Total Value: $732M (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| CGON | CG ONCOLOGY INC | 6,371,669 | $453M | 61.9% | — | — | COM | 156944100 |
| NUVB | Nuvation Bio Inc. | 25,954,439 | $147M | 20.1% | — | — | COM | 67080N101 |
| AARD | AARDVARK THERAPEUTICS INC | 3,917,299 | $22.56M | 3.1% | — | — | COM | 002942100 |
| ACRS | Aclaris Therapeutics, Inc. | 4,041,736 | $21.38M | 2.9% | — | — | COM | 00461U105 |
| UPB | Upstream Bio Inc. | 2,724,868 | $18.86M | 2.6% | — | — | COM | 91678A107 |
| RCUS | Arcus Biosciences, Inc | 464,779 | $14.33M | 2.0% | — | — | COM | 03969F109 |
| EQ | Equillium Inc. | 4,447,308 | $14.23M | 1.9% | — | — | COM | 29446K106 |
| RVMD | REVOLUTION MEDICINES INC(NSM) | 52,667 | $9.863M | 1.3% | — | — | COM | 76155X100 |
| — | Lyell Immunopharma, Inc. | 692,050 | $9.723M | 1.3% | — | — | COM | 55083R104 |
| BYSI | BeyondSpring Inc. | 3,800,702 | $6.651M | 0.9% | — | — | SHS | G10830100 |
| ZNTL | Zentalis Pharmaceuticals Inc. | 1,323,327 | $6.418M | 0.9% | — | — | COM | 98943L107 |
| NAMS | NEWAMSTERDAM PHARMA CO NV | 176,887 | $5.995M | 0.8% | — | — | COM | N62509109 |
| PYXS | Pyxis Oncology, Inc (formerly Apexigen) | 326,810 | $984K | 0.1% | — | — | COM | 747324101 |
| TNGX | TANGO THERAPEUTICS INC | 20,000 | $625K | 0.1% | — | — | COM | 87583X109 |